DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07021937

PLASTIC

Not yet recruitingPhase 3

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

120

estimated

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Hypothalamic functional activation•Hypothalamic functional connectivity•Ad libitum food intake

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07021937
Org study IDPending

Timeline

Milestones

Study first posted2025-06-15actual
Last update posted2025-06-15actual
Study start2026-05-01estimated
Primary completion2031-04-30estimated
Study completion2031-04-30estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age12 Years
Maximum age45 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•English-speaking
•male or female (sex assigned at birth)
•12-18 y/o with obesity (BMI>120% of the 95th %ile)
•30-45 y/o with obesity (BMI>35 kg/m2)

Exclusion criteria

•treated with glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, semaglutide, tirzepatide) for weight management in the prior 3 months
•currently taking anti-psychotic medications (anti-depressants accepted)
•diagnosis of type 2 diabetes
•current or lifetime anorexia nervosa or current bulimia nervosa
•head injury resulting in loss of consciousness >30min
•neurological disorder (e.g., Parkinson's disease) or history of stroke
•any contraindication to receiving a MRI (e.g., orthodontal braces)
•psychological/behavioral dysfunction (e.g., autism spectrum disorder) or physical impairment that would interfere with study procedures, as determined by study physician
•if female, desiring to become pregnant, or currently pregnant or breastfeeding

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Weight & body composition
1
Patient-reported / QoL
1

Weight & body composition

1 endpoint
Primary/protocol endpoint/low confidence

hypothalamic functional activation

Time frame:From enrollment to the end of trial at 32 weeks

descriptive

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

appetite sensations

Time frame:From enrollment to the end of trial at 32 weeks

change from baseline, improvement

Other (unclassified)

2 endpoints
Primary/protocol endpoint/low confidence

hypothalamic functional connectivity

Time frame:From enrollment to the end of trial at 32 weeks

descriptive

Primary/protocol endpoint/low confidence

ad libitum food intake

Time frame:From enrollment to the end of trial at 32 weeks

descriptive

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.